Stockwatch: The Blockbuster Delusion
This article was originally published in Scrip
Last week was one of changing fortunes as companies reported their first-quarter financial results. For a few days, the gloom of the previous week was lifted by the effects of growing sales of blockbuster products from Amgen and Roche by virtue of limited or in spite of exposure to the euro, respectively. However, by the end of last week we were back to doom and gloom again.
You may also be interested in...
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?
Debt-fueled acquisitions helped Teva, Shire and Allergan report well-received fourth-quarter earnings. But sector circumstances have changed since 2016 and the ability to grow by debt-funded acquisition is now severely restricted.